CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2
Authors:
- David A CooperDCDavid A Cooper
- Hernan ValdezHVHernan Valdez
- 1 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 54 (4) , 394-397
Abstract
Objectives: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. Methods: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. Results: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). Conclusions: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.Keywords
This publication has 11 references indexed in Scilit:
- A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1The Journal of Infectious Diseases, 2009
- Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384Clinical Infectious Diseases, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS DiseasesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- Correlates of Lending Needles/Syringes Among HIV-Seropositive Injection Drug UsersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy eraCurrent Opinion in Oncology, 2007
- HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General PopulationJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological responseAIDS, 2006